UOC
GLMD icon

UBS O'Connor’s Galmed Pharmaceuticals GLMD Stock Holding History

UBS O'Connor’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43
Closed -$503K – 270
2019
Q1 		$503K Sell
43
-31
-42% -$361K 0.01% 201
2018
Q4 		$726K Sell
74
-8
-10% -$112K 0.03% 179
2018
Q3 		$1.6M Sell
82
-5
-6% -$93.6K 0.04% 184
2018
Q2 		$1.49M Buy
+87
New +$1.01M 0.03% 178

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

UBS O'Connor's GLMD Position: Q2 2019 in Review

UBS O'Connor sold out of Galmed Pharmaceuticals (GLMD) in Q2 2019, closing a stake of 43 shares — an estimated $503K sold.

UBS O'Connor first reported a position in GLMD in Q2 2018 and held it in 4 quarters. The position peaked at $1.6M in Q3 2018. 31 funds tracked by Wall St. Rank hold GLMD as of Q2 2019.

  • UBS O'Connor reported no remaining Galmed Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • UBS O'Connor sold 43 Galmed Pharmaceuticals shares in Q2 2019, an estimated $503K.
  • UBS O'Connor first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • UBS O'Connor's Galmed Pharmaceuticals position peaked at $1.6M in Q3 2018.
  • 31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2019.

Based on UBS O'Connor's 13F filing for Q2 2019, filed 14 Aug 2019.